Unknown

Dataset Information

0

Novel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study.


ABSTRACT: Recent studies have revealed unique biological characteristics of molecular hydrogen (H2) as an anti-inflammatory agent. We developed a novel haemodialysis (E-HD) system delivering an H2 (30-80 ppb)-enriched dialysis solution by water electrolysis, and conducted a non-randomized, non-blinded, prospective observational study exploring its clinical impact. Prevalent chronic HD patients were allocated to either the E-HD (n?=?161) group or the conventional HD (C-HD: n?=?148) group, and received the respective HD treatments during the study. The primary endpoint was a composite of all-cause mortality and development of non-lethal cardio-cerebrovascular events (cardiac disease, apoplexy, and leg amputation due to peripheral artery disease). During the 3.28-year mean observation period, there were no differences in dialysis parameters between the two groups; however, post-dialysis hypertension was ameliorated with significant reductions in antihypertensive agents in the E-HD patients. There were 91 events (50 in the C-HD group and 41 in the E-HD group). Multivariate analysis of the Cox proportional hazards model revealed E-HD as an independent significant factor for the primary endpoint (hazard ratio 0.59; [95% confidence interval: 0.38-0.92]) after adjusting for confounding factors (age, cardiovascular disease history, serum albumin, and C-reactive protein). HD applying an H2-dissolved HD solution could improve the prognosis of chronic HD patients.

SUBMITTER: Nakayama M 

PROVIDER: S-EPMC5762770 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Novel haemodialysis (HD) treatment employing molecular hydrogen (H<sub>2</sub>)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study.

Nakayama Masaaki M   Itami Noritomo N   Suzuki Hodaka H   Hamada Hiromi H   Yamamoto Ryo R   Tsunoda Kazumasa K   Osaka Naoyuki N   Nakano Hirofumi H   Maruyama Yukio Y   Kabayama Shigeru S   Nakazawa Ryoichi R   Miyazaki Mariko M   Ito Sadayoshi S  

Scientific reports 20180110 1


Recent studies have revealed unique biological characteristics of molecular hydrogen (H<sub>2</sub>) as an anti-inflammatory agent. We developed a novel haemodialysis (E-HD) system delivering an H<sub>2</sub> (30-80 ppb)-enriched dialysis solution by water electrolysis, and conducted a non-randomized, non-blinded, prospective observational study exploring its clinical impact. Prevalent chronic HD patients were allocated to either the E-HD (n = 161) group or the conventional HD (C-HD: n = 148) gr  ...[more]

Similar Datasets

| S-EPMC10514616 | biostudies-literature
| S-EPMC3661003 | biostudies-literature
| S-EPMC11348812 | biostudies-literature
| S-EPMC6067402 | biostudies-literature
| S-EPMC9286659 | biostudies-literature
| S-EPMC5597210 | biostudies-literature
| S-EPMC5813026 | biostudies-literature
| S-EPMC9572675 | biostudies-literature
| S-EPMC9490610 | biostudies-literature
| S-EPMC6772054 | biostudies-literature